Furthermore, combination treatment using QLT-0267 and dasatinib increases survival in xenograft models of advanced CML and reduces long-term engraftment of human LSCs in patient-derived xenograft (PDX) models using primary CML patient samples, [75], implicating ILK as an adjuvant target in CML [75]. The gene discussed is ILK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.